HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer.

Tao Jiang Qiqi Jin Jiahao Wang Feng-Ying Wu Jian Chen Gongyan Chen Yunchao Huang Jianhua Chen Ying Cheng Qi-Ming Wang Yue-Yin Pan Jian-Ying Zhou Jianhua Shi Xingxiang Xu LiZhu Lin Wei Zhang Yiping Zhang Yun-Peng Liu Yong Fang Jifeng Feng Zhehai Wang Sheng Hu Jian Fang Yongqian Shu Jiu-Wei Cui Yi Hu Wenxiu Yao Xingya Li Xiaoyan Lin Rui Wang Yongsheng Wang Wei Shi Gaohua Feng Jun Ni Beibei Mao Dandan Ren Huaibo Sun Henghui Zhang Luo-Nan Chen Cai-Cun Zhou Shengxiang Ren

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

These findings suggest that high HED could portend survival benefit in advanced NSCLC treated with first-line PD-1 blockade plus chemotherapy.

Keyphrases